ATE455558T1 - Modifiziertes adenovirus-hexon-protein und anwendungen davon - Google Patents

Modifiziertes adenovirus-hexon-protein und anwendungen davon

Info

Publication number
ATE455558T1
ATE455558T1 AT07835738T AT07835738T ATE455558T1 AT E455558 T1 ATE455558 T1 AT E455558T1 AT 07835738 T AT07835738 T AT 07835738T AT 07835738 T AT07835738 T AT 07835738T AT E455558 T1 ATE455558 T1 AT E455558T1
Authority
AT
Austria
Prior art keywords
hexon protein
applications
modified adenovirus
adenovirus hexon
adenovirus
Prior art date
Application number
AT07835738T
Other languages
English (en)
Inventor
Soumitra Roy
James Wilson
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of ATE455558T1 publication Critical patent/ATE455558T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT07835738T 2006-04-28 2007-04-27 Modifiziertes adenovirus-hexon-protein und anwendungen davon ATE455558T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79607806P 2006-04-28 2006-04-28
PCT/US2007/010347 WO2008010864A2 (en) 2006-04-28 2007-04-27 Modified adenovirus hexon protein and uses thereof

Publications (1)

Publication Number Publication Date
ATE455558T1 true ATE455558T1 (de) 2010-02-15

Family

ID=38957245

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07835738T ATE455558T1 (de) 2006-04-28 2007-04-27 Modifiziertes adenovirus-hexon-protein und anwendungen davon

Country Status (15)

Country Link
US (3) US20090074810A1 (de)
EP (1) EP2012822B1 (de)
JP (1) JP5889514B2 (de)
CN (1) CN101437538A (de)
AT (1) ATE455558T1 (de)
CY (1) CY1110002T1 (de)
DE (1) DE602007004470D1 (de)
DK (1) DK2012822T3 (de)
ES (1) ES2341501T3 (de)
HR (1) HRP20100228T1 (de)
PL (1) PL2012822T3 (de)
PT (1) PT2012822E (de)
RS (1) RS51250B (de)
SI (1) SI2012822T1 (de)
WO (1) WO2008010864A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002322285A1 (en) * 2001-06-22 2003-01-08 The Trustees Of The University Of Pennsylvania Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
MXPA04004876A (es) 2001-11-21 2004-07-30 Univ Pennsylvania Secuencias de acido nucleico y de aminoacido de adenovirus de simio, vectores que contienen los mismos y metodos de uso.
CA2567741A1 (en) 2004-05-25 2006-03-30 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
JP2009533350A (ja) 2006-04-07 2009-09-17 キメロス， インコーポレイテッド Ｂ細胞悪性疾患を処置するための組成物および方法
EP2220217A2 (de) * 2007-11-28 2010-08-25 The Trustees of the University of Pennsylvania Simian-adenoviren sadv-40, -31 und-34 der unterfamilie c und anwendungen davon
DK2220242T3 (en) 2007-11-28 2017-03-27 Univ Pennsylvania ABE-ADENOVIRA OF GROUP B, SADV-28,27, -29, -32, -33 AND -35 AND APPLICATIONS THEREOF
CN101883858B (zh) * 2007-11-28 2015-07-22 宾夕法尼亚大学托管会 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用
JP5661476B2 (ja) 2008-03-04 2015-01-28 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルアデノウイルスＳＡｄＶ−３６、−４２．１、−４２．２および−４４ならびにそれらの用途
WO2010051367A1 (en) 2008-10-31 2010-05-06 The Trustees Of The University Of Pennsylvania Simian adenoviruses sadv-43, -45,-48,-49, and -50 and uses thereof
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
CA2762203A1 (en) 2009-05-29 2010-12-02 Soumitra Roy Simian adenovirus 41 and uses thereof
WO2011014794A1 (en) 2009-07-31 2011-02-03 Paxvax, Inc. Adenoviral-based vectors
JP5785607B2 (ja) * 2010-04-14 2015-09-30 モガム バイオテクノロジー リサーチ インスティチュート サルアデノウイルス血清型１９から単離されたヘキソン、その超可変領域、およびそれらを用いるキメラアデノウイルス
EP2643465B1 (de) 2010-11-23 2016-05-11 The Trustees Of The University Of Pennsylvania Affen-adenovirus a1321 der subfamilie e und verwendungen davon
EP2747774A4 (de) 2011-09-09 2015-02-11 Biomed Realty L P Verfahren und zusammensetzungen zur kontrolle einer virusproteinassemblierung
CN103242433B (zh) * 2012-02-14 2016-12-14 中国医学科学院病原生物学研究所 一种腺病毒非结构蛋白免疫原、其抗体及应用
SG10201609511XA (en) 2012-05-18 2016-12-29 Univ Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
US9222142B2 (en) * 2013-01-15 2015-12-29 The Regents Of The University Of California Adenoviruses and their use
EP2971008B1 (de) 2013-03-14 2018-07-25 Salk Institute for Biological Studies Onkolytische adenoviruszusammensetzungen
BR112016008806A2 (pt) 2013-11-01 2017-10-03 Pfizer Vetores para expressão de antígenos associados à próstata
CN103865923B (zh) * 2014-01-28 2017-04-26 中国人民解放军第三0二医院 流感病毒为载体的HAdV嵌合疫苗的制备及其应用
EP2940128A1 (de) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus mit einem albuminbindenden Teil
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
BR112017009497A2 (pt) 2014-11-05 2018-02-06 Voyager Therapeutics, Inc. polinucleotídeos de aadc para o tratamento da doença de parkinson
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
BR112017010087A2 (pt) 2014-11-14 2018-06-05 Voyager Therapeutics, Inc. composições e métodos para tratar esclerose lateral amiotrófica (ela)
EP3230441A4 (de) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur herstellung von scaav
CN107406859A (zh) 2015-03-17 2017-11-28 倾斜生物医疗公司 编码双特异性抗体的溶瘤腺病毒及与其相关的方法和用途
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
AU2017223460A1 (en) * 2016-02-23 2018-09-13 Immune Design Corp. Multigenome retroviral vector preparations and methods and systems for producing and using same
EP3448987A4 (de) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. Zusammensetzungen zur behandlung einer erkrankung
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
MX2018014154A (es) 2016-05-18 2019-05-06 Voyager Therapeutics Inc Polinucleotidos moduladores.
RU2764587C2 (ru) 2016-05-18 2022-01-18 Вояджер Терапьютикс, Инк. Способы и композиции для лечения хореи гентингтона
EP3831281A1 (de) 2016-08-30 2021-06-09 The Regents of The University of California Verfahren für biomedizinisches targeting und freisetzung sowie vorrichtungen und systeme zur ausführung davon
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
CN106754760A (zh) * 2017-01-20 2017-05-31 华南农业大学 一种嵌合ibdv中和表位的重组人3型腺病毒的制备方法和应用
EP3619308A4 (de) 2017-05-05 2021-01-27 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von morbus huntington
AU2018261790A1 (en) 2017-05-05 2019-11-28 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
WO2019018342A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. NETWORK EQUIPMENT TRACK GUIDE SYSTEM
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
EP4124658A3 (de) 2017-10-16 2023-04-19 Voyager Therapeutics, Inc. Behandlung von amyotropher lateralsklerose (als)
US11773142B2 (en) 2017-12-11 2023-10-03 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and uses thereof
EP3927833A4 (de) * 2019-02-21 2022-11-30 Unleash Immuno Oncolytics, Inc. Onkolytischer adenoviraler vektor und verfahren zur verwendung

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465253B1 (en) * 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
WO1998010087A1 (en) * 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6211160B1 (en) * 1996-09-06 2001-04-03 The Trustees Of The University Of Pennsylvania Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
JP2002523105A (ja) * 1998-08-27 2002-07-30 アバンテイス・フアルマ・エス・アー 異種遺伝子の運搬用の標的化アデノウイルスベクター
US6955808B2 (en) * 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
MXPA04004876A (es) * 2001-11-21 2004-07-30 Univ Pennsylvania Secuencias de acido nucleico y de aminoacido de adenovirus de simio, vectores que contienen los mismos y metodos de uso.
EP1388541A1 (de) * 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazine als Kinasehemmer
US7291498B2 (en) * 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
ES2478625T3 (es) * 2003-06-20 2014-07-22 The Trustees Of The University Of Pennsylvania Método de generación de adenovirus quiméricos y usos de tales adenovirus quiméricos
US7144712B2 (en) * 2003-07-30 2006-12-05 Vaccine Research Institute Of San Diego Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
FR2860004A1 (fr) * 2003-09-18 2005-03-25 Roussy Inst Gustave Nouveau vecteur adenoviral pour l'infection de cellules deficientes ou depourvues en recepteurs car

Also Published As

Publication number Publication date
DK2012822T3 (da) 2010-05-25
PL2012822T3 (pl) 2010-06-30
US20170096646A1 (en) 2017-04-06
WO2008010864A3 (en) 2008-05-02
US20090074810A1 (en) 2009-03-19
PT2012822E (pt) 2010-04-27
RS51250B (sr) 2010-12-31
US20160102295A1 (en) 2016-04-14
HRP20100228T1 (hr) 2010-07-31
WO2008010864A2 (en) 2008-01-24
EP2012822B1 (de) 2010-01-20
ES2341501T3 (es) 2010-06-21
DE602007004470D1 (de) 2010-03-11
EP2012822A2 (de) 2009-01-14
JP2009535032A (ja) 2009-10-01
JP5889514B2 (ja) 2016-03-22
SI2012822T1 (sl) 2010-06-30
CN101437538A (zh) 2009-05-20
CY1110002T1 (el) 2015-01-14

Similar Documents

Publication Publication Date Title
ATE455558T1 (de) Modifiziertes adenovirus-hexon-protein und anwendungen davon
CY1119967T1 (el) Αναστολη πρωτεασης
DE602006015793D1 (de) Proteolipidmembran und lipidmembranen-biosensor
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
MA32535B1 (fr) Compositions et procédés pour des anticorps ciblant une protéine du complément c5
FI20051318A (fi) Selluloosapitoisen materiaalin käsittely ja siihen käytettäviä entsyymejä
TNSN08391A1 (en) Lyophilized therapeutic peptibody formulations
ATE534383T1 (de) Zusammensetzungen aus n-ä2,4-bis(1,1- dimethylethyl)-5-hydroxyphenylü-1,4-dihydro-4- oxochinolin-3-carboxamid
ATE537263T1 (de) Kationische lipide und verwendungsverfahren
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
EP1828219A4 (de) Sirna-silencing von apolipoprotein b
AU305551S (en) Bottle
SG166813A1 (en) 5-lipoxygenase-activating protein (flap) inhibitors
SG165387A1 (en) 5-lipoxygenase-activating protein (flap) inhibitors
DE602008002693D1 (de) Vakzine-peptid-kombinationen gegen katzenallergie
EP2354224A4 (de) Neues protein mit fructosyl-valyl-histidinoxidaseaktivität, modifiziertes produkt daraus und verwendung des proteins oder modifizierten produkts
CR10263A (es) Induccion y estabilizacion de actividad enzimatica en microorganismos
MX2007015935A (es) Agentes y metodos basados en el uso del dominio eda de la fibronectina.
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
FR2896693B1 (fr) Composition comprenant plusieurs toxines botuliques
AU311467S (en) Thermometer
AU316238S (en) Lawning applicator for microbiological cultures
ITFI20070287A1 (it) "un complesso espositore per la presentazione al pubblico di prodotti confezionati, con attivatori ottici e/o acustici"
ITRM20050478A1 (it) Apparato per l'applicazione contemporanea della carbossiterapia e della mesoterapia.
HK1118276A1 (en) Ethanolamine salt of n-(3-methoxy-5-methylpyrazin-2yl)-2-(4-[1,3,4- oxadiazole-2-yl]phenyl)pyridine-3-sulphonamide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2012822

Country of ref document: EP